Datasets:
Tasks:
Text Classification
Modalities:
Text
Formats:
parquet
Languages:
English
Size:
100K - 1M
Tags:
biology
immunology
antibodies
protein-protein-interactions
drug-discovery
computational-biology
License:
| dataset_info: | |
| features: | |
| - name: dataset | |
| dtype: string | |
| - name: heavy_sequence | |
| dtype: string | |
| - name: light_sequence | |
| dtype: string | |
| - name: scfv | |
| dtype: bool | |
| - name: affinity_type | |
| dtype: string | |
| - name: affinity | |
| dtype: string | |
| - name: antigen_sequence | |
| dtype: string | |
| - name: confidence | |
| dtype: | |
| class_label: | |
| names: | |
| '0': medium | |
| '1': high | |
| '2': very_high | |
| - name: nanobody | |
| dtype: bool | |
| - name: processed_measurement | |
| dtype: float64 | |
| - name: target_name | |
| dtype: string | |
| - name: target_pdb | |
| dtype: string | |
| - name: target_uniprot | |
| dtype: string | |
| - name: source_url | |
| dtype: string | |
| - name: heavy_cdr1 | |
| dtype: string | |
| - name: heavy_cdr2 | |
| dtype: string | |
| - name: heavy_cdr3 | |
| dtype: string | |
| - name: light_cdr1 | |
| dtype: string | |
| - name: light_cdr2 | |
| dtype: string | |
| - name: light_cdr3 | |
| dtype: string | |
| splits: | |
| - name: train | |
| num_bytes: 2137958513 | |
| num_examples: 1227083 | |
| download_size: 339997839 | |
| dataset_size: 2137958513 | |
| configs: | |
| - config_name: default | |
| data_files: | |
| - split: train | |
| path: data/train-* | |
| pretty_name: 'AgAb DB: Antigen Specific Antibody Database' | |
| tags: | |
| - biology | |
| - immunology | |
| - antibodies | |
| - protein-protein-interactions | |
| - drug-discovery | |
| - computational-biology | |
| - therapeutics | |
| - machine-learning | |
| - protein-sequence-modeling | |
| - binding-affinity-prediction | |
| - antibody-design | |
| task_categories: | |
| - text-classification | |
| license: other | |
| license_details: "Non-commercial research use only. Commercial inquiries should be directed to NaturalAntibody." | |
| language: | |
| - en | |
| # AgAb DB: Antigen Specific Antibody Database | |
| A comprehensive collection of antibody-antigen interaction data for computational biology and therapeutic design. | |
| ## Dataset Summary | |
| AgAb DB aggregates antibody-antigen binding data from multiple sources, containing over 1.2 million antibody-antigen pairs with binding affinity measurements. This dataset is essential for training machine learning models in computational immunology and antibody engineering. | |
| ## Key Statistics | |
| - **1,227,083** antibody-antigen interaction records | |
| - **309,884** unique antibodies (full antibodies, nanobodies, scFvs) | |
| - **4,334** unique antigens | |
| - **170,660** complete heavy/light chain pairs | |
| - **70,388** nanobodies and **132,157** scFv antibodies | |
| - **Focus on human health**: Infectious diseases, cancer, autoimmune conditions | |
| - **Diverse antigen types**: Viral proteins, bacterial antigens, cancer markers, autoantigens | |
| *Note: Statistics for unique antibodies/antigens are from original documentation and may be proportionally larger in the full 1.2M record dataset.* | |
| ### Data Quality Distribution | |
| - **51% very_high confidence** (robust sequences and methodology) | |
| - **high confidence** (manually curated datasets) | |
| - **medium confidence** (automated discovery, some uncertainty) | |
| ### Affinity Measurement Types | |
| - Quantitative metrics: Gibbs free energy changes, kinetic constants, IC₅₀ | |
| - Qualitative binding assessments | |
| - Mixed data types across different sources | |
| ## Data Structure | |
| ### Core Fields | |
| | Field | Type | Description | | |
| |-------|------|-------------| | |
| | `heavy_sequence` | string | Antibody heavy chain amino acid sequence | | |
| | `light_sequence` | string | Antibody light chain amino acid sequence | | |
| | `antigen_sequence` | string | Target antigen amino acid sequence | | |
| | `affinity` | string | Binding affinity value | | |
| | `confidence` | string | Data quality level (very_high, high, medium) | | |
| ### Additional Metadata | |
| | Field | Type | Description | | |
| |-------|------|-------------| | |
| | `dataset` | string | Original source dataset | | |
| | `affinity_type` | string | Measurement type (KD, IC₅₀, etc.) | | |
| | `nanobody` | bool | Whether it's a nanobody | | |
| | `scfv` | bool | Single-chain variable fragment | | |
| | `target_name` | string | Antigen name | | |
| | `target_pdb` | string | PDB structure ID | | |
| | `target_uniprot` | string | UniProt accession | | |
| | `heavy_cdr1/cdr2/cdr3` | string | Complementarity-determining regions | | |
| | `light_cdr1/cdr2/cdr3` | string | Light chain CDRs | | |
| ## Dataset Split | |
| - **Train**: All 1,227,083 records in a single training set | |
| The full dataset is provided as a single training split to maximize available data for machine learning applications. Users can create their own validation/test splits as needed for their specific use cases. | |
| ### Confidence Categories | |
| - **very_high**: Both sequences and methodology used for calculating affinity were robust (e.g., AbDesign, BioMap, SKEMPI 2.0) | |
| - **high**: Manually curated datasets or those containing antigen names/mutations rather than full sequences (e.g., FLAB datasets) | |
| - **medium**: Automated data discovery with some uncertainty (e.g., patent databases) | |
| ### Antibody Types Included | |
| - **Full antibodies**: Complete heavy and light chain pairs (traditional monoclonal antibodies) | |
| - **Nanobodies**: Single-domain antibodies (VHH format) - 70K+ entries across datasets | |
| - **scFv**: Single-chain variable fragments - 132K+ entries, primarily from AlphaSeq | |
| - **Mixed formats**: Various antibody fragment types and engineered variants | |
| ### Nanobody Distribution by Source | |
| | Source | Nanobody Count | Notes | | |
| |--------|----------------|-------| | |
| | AlphaSeq | 67,058 | Mutations for improved binding | | |
| | Patents | 40,517 | Patent literature extraction | | |
| | Literature | 1,936 | Research paper curation | | |
| | Structures | 1,258 | PDB structure-derived | | |
| | AATP, OSH, RMNA | ~133 | Specialized datasets | | |
| ### scFv Distribution by Source | |
| | Source | scFv Count | Notes | | |
| |--------|------------|-------| | |
| | AlphaSeq | 131,645 | Primary scFv source | | |
| | Literature | 512 | Research paper curation | | |
| ### Sequence Characteristics | |
| - **Predominantly short sequences**: <150 amino acids typical | |
| - **Majority include both chains**: Heavy and light chain pairs | |
| - **Diverse antigen targets**: Infectious diseases, cancer, autoimmune conditions | |
| - **Multiple affinity measurement types**: KD, IC₅₀, ΔG, binary binding | |
| ## Usage | |
| ### Load the Dataset | |
| ```python | |
| from datasets import load_dataset | |
| # Load from OpenMed | |
| dataset = load_dataset("OpenMed/agab-db") | |
| # Access the training data (full dataset) | |
| train_data = dataset["train"] | |
| # Optional: Create your own validation/test splits | |
| from sklearn.model_selection import train_test_split | |
| import pandas as pd | |
| # Convert to pandas for splitting | |
| df = pd.DataFrame(train_data) | |
| train_df, test_df = train_test_split(df, test_size=0.1, random_state=42) | |
| train_df, val_df = train_test_split(train_df, test_size=0.1, random_state=42) | |
| ``` | |
| ### Filter for Research | |
| ```python | |
| # High-quality data only | |
| high_quality = dataset.filter(lambda x: x["confidence"] == "very_high") | |
| # Nanobodies for specialized studies | |
| nanobodies = dataset.filter(lambda x: x["nanobody"] == True) | |
| # Specific antigens | |
| covid_data = dataset.filter(lambda x: "covid" in x["target_name"].lower()) | |
| ``` | |
| ### Prepare for ML Training | |
| ```python | |
| # Extract sequences for language models | |
| sequences = [] | |
| for item in dataset["train"]: | |
| if item["heavy_sequence"]: | |
| sequences.append(item["heavy_sequence"]) | |
| if item["light_sequence"]: | |
| sequences.append(item["light_sequence"]) | |
| ``` | |
| ## Applications | |
| ### Machine Learning Use Cases | |
| - **Antibody language models**: Train sequence models on antibody repertoires for generative design | |
| - **Binding affinity prediction**: Develop regression models for antibody-antigen interaction strength | |
| - **Therapeutic design**: Guide rational antibody engineering and optimization | |
| - **Computational immunology**: Study immune responses and antibody development patterns | |
| - **Virtual screening**: Prioritize antibody candidates for experimental validation | |
| - **Structure-affinity relationships**: Learn connections between 3D structures and binding properties | |
| ### Research Applications | |
| - **Antibody repertoire analysis**: Study natural antibody diversity and evolution | |
| - **Cross-reactivity prediction**: Identify potential off-target effects | |
| - **Immunogenicity assessment**: Predict antibody developability and safety | |
| - **Drug discovery pipelines**: Accelerate hit identification and lead optimization | |
| - **Comparative immunology**: Study antibody responses across different species | |
| ### Integration with Other Tools | |
| - **Protein structure prediction**: Use with ESMFold for 3D structure generation | |
| - **Molecular dynamics**: Combine with simulation tools for binding mechanism studies | |
| - **High-throughput screening**: Guide experimental antibody library screening | |
| - **CRISPR engineering**: Design antibodies for gene therapy applications | |
| ## Data Sources | |
| Aggregated from 25+ datasets including GenBank, SKEMPI 2.0, peer-reviewed publications, and patent databases. | |
| ### Major Dataset Components | |
| | Dataset | Records | Unique Antibodies | Key Characteristics | | |
| |---------|---------|-------------------|-------------------| | |
| | **BUZZ** | 524,346 | 524,346 | Trastuzumab mutations binding to HER2 | | |
| | **AlphaSeq** | 198,703 | 193,867 | Antibody mutations across 4 targets (TIGIT, SARS-CoV2-RBD, PD-1, HER2) | | |
| | **ABBD** | 155,853 | 88,946 | Eight antibody-antigen cases with heavy chain mutations | | |
| | **Patents** | 217,463 | 31,173 | NLP-extracted sequences from patent literature | | |
| | **COVID-19** | 27,301 | 6,759 | SARS-CoV-2 neutralization data (Cov-AbDab) | | |
| | **HIV** | 48,008 | 192 | HIV-targeting antibodies (LANL database) | | |
| | **BioMap** | 2,725 | 728 | Binding ΔG values across 8 species | | |
| | **Literature** | 5,580 | 4,841 | Curated from research articles (1,940 nanobodies) | | |
| | **FLAB** | 6,849 | 6,798 | Five publications on viral/cancer targets | | |
| | **ABDesign** | 672 | 672 | Systematic CDR-H3 point mutations | | |
| ### Inclusion Criteria | |
| - Transparency and completeness of data | |
| - Relevance to human health | |
| - Quantitative binding affinity measurements | |
| - Complete amino acid sequences for all biomolecules | |
| ### Data Processing Pipeline | |
| 1. **Aggregation**: Collection from 14 distinct sources → 25 integrated datasets | |
| 2. **Curation**: Multi-stage pipeline with automated extraction, normalization, and manual verification | |
| 3. **Standardization**: Common structure implemented across all studies | |
| 4. **Validation**: Automated feasibility checks and manual verification of critical datasets | |
| ## Citation | |
| ```bibtex | |
| @dataset{agab_db, | |
| title={AgAb DB: Antigen Specific Antibody Database}, | |
| author={NaturalAntibody}, | |
| year={2024}, | |
| url={https://naturalantibody.com/agab/} | |
| } | |
| ``` | |
| ## License | |
| Available for non-commercial research use only. Contact NaturalAntibody for commercial licensing. | |
| --- | |
| *Dataset provided by [NaturalAntibody](https://naturalantibody.com/agab/)* | |